Investment Trusts

BioPharma Credit PLC

BPCR:LSE

BioPharma Credit PLC

Actions
  • Price (USD)0.99
  • Today's Change-0.006 / -0.60%
  • Shares traded3.33m
  • 1 Year change-0.23%
  • Beta0.2480
Data delayed at least 20 minutes, as of Jan 27 2021 17:19 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Total returns on $1000

1Y
Fund/benchmarkChange
PriceBioPharma Credit PLC (Ordinary Share)--
NAVBioPharma Credit PLC (Ordinary Share)+7.63%
Morningstar's BenchmarkAIC Inv Trust - Split - Zero Divi--

Key statistics

On Wednesday, BioPharma Credit PLC (BPCR:LSE) closed at 0.99, -3.88% below its 52-week high of 1.03, set on Sep 14, 2020.
52-week range
Today
0.6995Apr 06 20201.03Sep 14 2020
Markit short selling activity
Low
Med
High
Shares outstanding1.37bn
Market cap1.37bn USD
Total assets1.37bn USD
Total expense ratio1.12%
High0.998
Low0.99
Previous close0.996
Average volume976.20k
YTD Change-0.60%
Beta0.2480%
Diluted NAV (est)1.00
Diluted NAV (last pub)1.00
Premium/Discount-0.40%
Gearing0.00%
Annual div (ADY)0.07
USD
Annual div yield (ADY)7.03%
Div ex-dateNov 19 2020
Div pay-dateDec 18 2020
Data delayed at least 20 minutes, as of Jan 27 2021 17:19 GMT.
More ▼
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.